Hers Health, Inc. Reports Third Quarter 2026 Financial Results

Hims & Hers Health (NYSE: HIMS) announced third-quarter 2026 results after the market closed on November 9, 2026. The company reported revenue of $401.6 million, a 69% increase from the same quarter a year earlier, and total subscribers of 2.2 million, up 54% year over year, according to the company's investor relations release and Reuters. Net loss widened to $14.9 million, or $0.07 per share, compared with a net loss of $3.2 million, or $0.02 per share, in Q3 2025. Adjusted EBITDA was $33.1 million, representing an 8.2% margin, down from $24.5 million and a 10.3% margin a year earlier.

The company narrowed its full-year 2026 revenue guidance to $1.53 billion to $1.55 billion, down from a prior range of $1.54 billion to $1.58 billion, and lowered its adjusted EBITDA outlook to $130 million to $135 million from $140 million to $150 million previously. The Wall Street Journal reported that the midpoint of the new revenue range implies about 55% growth for the year, while the adjusted EBITDA midpoint suggests a margin near 8.7%, below the roughly 9.5% margin implied by the prior guide. Reuters said the company cited higher marketing spend, increased costs from its GLP-1 weight-loss offerings, and continued investment in international expansion and AI tools as reasons for the margin pressure.

Shares fell about 15% in after-hours trading following the release, according to Yahoo Finance and Investor's Business Daily. Quiver Quantitative noted the stock was down 7.3% during the regular session ahead of the report, as investors weighed the recent expansion of access to Eli Lilly's branded obesity medicines Zepbound and Foundayo through the Hims & Hers platform. The company said the agreement allows eligible patients to access those medicines, but analysts have questioned whether the arrangement will compress margins or increase operating costs. Barron's and Benzinga highlighted that the market reaction reflects concern over the path to profitability amid rapid top-line growth. The company's next earnings release has not been dated in the provided materials.